GlassScriptPhysician profile
Abigale Henry
NPI 1598151615
$1,882.95
in general payments reported to CMS, 2019-2025
24 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $804 · 2023: $334 · 2024: $430 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.96 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $341.35 | 2021-2024 | Breztri, Airsupra, Andexxa |
| Glaxosmithkline, LLC. | $334.13 | 2022-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.73 | 2021-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $144.27 | 2022-2025 | Opsumit, Uptravi |
| Shionogi INC | $126.26 | 2022-2024 | Fetroja |
| Baxter Healthcare | $97.15 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $77.23 | 2022-2024 | Yupelri |
| Amgen INC. | $60.04 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.20 | 2022-2023 | Glassia |
| United Therapeutics Corporation | $53.18 | 2024 | Tyvaso |
| Covis Pharma Gmbh | $47.86 | 2022-2023 | |
| Harmony Biosciences LLC | $46.81 | 2022 | |
| Genzyme Corporation | $43.57 | 2022 | |
| Merck Sharp & Dohme LLC | $43.03 | 2021-2023 | Zerbaxa, Dificid, Recarbrio |
| Inspire Medical Systems, INC. | $40.08 | 2025 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37.41 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $28.63 | 2021 | |
| Atricure, INC. | $25.92 | 2023 | |
| Body Vision Medical INC. | $24.61 | 2024 | Lungvision |
| Ani Pharmaceuticals, INC. | $22.29 | 2024 | Purified Cortrophin Gel |
| Grifols USA, LLC | $22.27 | 2022 | |
| Nabriva Therapeutics, Plc | $20.70 | 2022 | |
| Philips North America LLC | $15.36 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.87 | 2024 | Vibativ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigale Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.